Splenectomy in patients with myeloproliferative neoplasms: Efficacy, complications and impact on survival and transformation

Fabio P.S. Santos, Constantine S. Tam, Hagop Kantarjian, Jorge Cortes, Deborah Thomas, Raphael Pollock, Srdan Verstovsek

Research output: Contribution to journalArticle

Abstract

Splenectomy may be an effective therapeutic option for treating massive splenomegaly in patients with myeloproliferative neoplasms (MPNs). There are still limited data on its short- and long-term benefits and risks. Efficacy and short-term complications were analyzed in 94 patients with different MPNs who underwent splenectomy at M. D. Anderson Cancer Center. The long-term impact of splenectomy on overall survival (OS) and transformation free survival (TFS) was evaluated in 461 patients with myelofibrosis (MF) seen at M. D. Anderson, including 50 who underwent splenectomy during disease evolution. Splenectomy improved anemia and thrombocytopenia in 47% and 66% of patients, respectively. The most common complications were leukocytosis (76%), thrombocytosis (43%) and venous thromboembolism (16%). Post-operative mortality was 5%. Among patients with MF, splenectomy during disease evolution was associated with decreased OS (hazard ratio [HR] = 2.17, p < 0.0001) and TFS (HR = 2.17, p < 0.0001). This effect was independent of the Dynamic International Prognostic Scoring System. Splenectomy is a possible therapeutic option for patients with MF and other MPNs, and its greatest benefits are related to improvement in spleen pain and discomfort, anemia and thrombocytopenia. However, in patients with MF it appears to be associated with increased mortality.

Original languageEnglish (US)
Pages (from-to)121-127
Number of pages7
JournalLeukemia and Lymphoma
Volume55
Issue number1
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Splenectomy
Primary Myelofibrosis
Survival
Neoplasms
Thrombocytopenia
Anemia
Thrombocytosis
Mortality
Splenomegaly
Venous Thromboembolism
Leukocytosis
Spleen
Pain
Therapeutics

Keywords

  • Acute myeloid leukemia
  • Myelofibrosis
  • Myeloproliferative neoplasms
  • Splenectomy
  • Survival

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Splenectomy in patients with myeloproliferative neoplasms : Efficacy, complications and impact on survival and transformation. / Santos, Fabio P.S.; Tam, Constantine S.; Kantarjian, Hagop; Cortes, Jorge; Thomas, Deborah; Pollock, Raphael; Verstovsek, Srdan.

In: Leukemia and Lymphoma, Vol. 55, No. 1, 01.01.2014, p. 121-127.

Research output: Contribution to journalArticle

Santos, Fabio P.S. ; Tam, Constantine S. ; Kantarjian, Hagop ; Cortes, Jorge ; Thomas, Deborah ; Pollock, Raphael ; Verstovsek, Srdan. / Splenectomy in patients with myeloproliferative neoplasms : Efficacy, complications and impact on survival and transformation. In: Leukemia and Lymphoma. 2014 ; Vol. 55, No. 1. pp. 121-127.
@article{0241ea3b7e9142919548404910d9d6d8,
title = "Splenectomy in patients with myeloproliferative neoplasms: Efficacy, complications and impact on survival and transformation",
abstract = "Splenectomy may be an effective therapeutic option for treating massive splenomegaly in patients with myeloproliferative neoplasms (MPNs). There are still limited data on its short- and long-term benefits and risks. Efficacy and short-term complications were analyzed in 94 patients with different MPNs who underwent splenectomy at M. D. Anderson Cancer Center. The long-term impact of splenectomy on overall survival (OS) and transformation free survival (TFS) was evaluated in 461 patients with myelofibrosis (MF) seen at M. D. Anderson, including 50 who underwent splenectomy during disease evolution. Splenectomy improved anemia and thrombocytopenia in 47{\%} and 66{\%} of patients, respectively. The most common complications were leukocytosis (76{\%}), thrombocytosis (43{\%}) and venous thromboembolism (16{\%}). Post-operative mortality was 5{\%}. Among patients with MF, splenectomy during disease evolution was associated with decreased OS (hazard ratio [HR] = 2.17, p < 0.0001) and TFS (HR = 2.17, p < 0.0001). This effect was independent of the Dynamic International Prognostic Scoring System. Splenectomy is a possible therapeutic option for patients with MF and other MPNs, and its greatest benefits are related to improvement in spleen pain and discomfort, anemia and thrombocytopenia. However, in patients with MF it appears to be associated with increased mortality.",
keywords = "Acute myeloid leukemia, Myelofibrosis, Myeloproliferative neoplasms, Splenectomy, Survival",
author = "Santos, {Fabio P.S.} and Tam, {Constantine S.} and Hagop Kantarjian and Jorge Cortes and Deborah Thomas and Raphael Pollock and Srdan Verstovsek",
year = "2014",
month = "1",
day = "1",
doi = "10.3109/10428194.2013.794269",
language = "English (US)",
volume = "55",
pages = "121--127",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Splenectomy in patients with myeloproliferative neoplasms

T2 - Efficacy, complications and impact on survival and transformation

AU - Santos, Fabio P.S.

AU - Tam, Constantine S.

AU - Kantarjian, Hagop

AU - Cortes, Jorge

AU - Thomas, Deborah

AU - Pollock, Raphael

AU - Verstovsek, Srdan

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Splenectomy may be an effective therapeutic option for treating massive splenomegaly in patients with myeloproliferative neoplasms (MPNs). There are still limited data on its short- and long-term benefits and risks. Efficacy and short-term complications were analyzed in 94 patients with different MPNs who underwent splenectomy at M. D. Anderson Cancer Center. The long-term impact of splenectomy on overall survival (OS) and transformation free survival (TFS) was evaluated in 461 patients with myelofibrosis (MF) seen at M. D. Anderson, including 50 who underwent splenectomy during disease evolution. Splenectomy improved anemia and thrombocytopenia in 47% and 66% of patients, respectively. The most common complications were leukocytosis (76%), thrombocytosis (43%) and venous thromboembolism (16%). Post-operative mortality was 5%. Among patients with MF, splenectomy during disease evolution was associated with decreased OS (hazard ratio [HR] = 2.17, p < 0.0001) and TFS (HR = 2.17, p < 0.0001). This effect was independent of the Dynamic International Prognostic Scoring System. Splenectomy is a possible therapeutic option for patients with MF and other MPNs, and its greatest benefits are related to improvement in spleen pain and discomfort, anemia and thrombocytopenia. However, in patients with MF it appears to be associated with increased mortality.

AB - Splenectomy may be an effective therapeutic option for treating massive splenomegaly in patients with myeloproliferative neoplasms (MPNs). There are still limited data on its short- and long-term benefits and risks. Efficacy and short-term complications were analyzed in 94 patients with different MPNs who underwent splenectomy at M. D. Anderson Cancer Center. The long-term impact of splenectomy on overall survival (OS) and transformation free survival (TFS) was evaluated in 461 patients with myelofibrosis (MF) seen at M. D. Anderson, including 50 who underwent splenectomy during disease evolution. Splenectomy improved anemia and thrombocytopenia in 47% and 66% of patients, respectively. The most common complications were leukocytosis (76%), thrombocytosis (43%) and venous thromboembolism (16%). Post-operative mortality was 5%. Among patients with MF, splenectomy during disease evolution was associated with decreased OS (hazard ratio [HR] = 2.17, p < 0.0001) and TFS (HR = 2.17, p < 0.0001). This effect was independent of the Dynamic International Prognostic Scoring System. Splenectomy is a possible therapeutic option for patients with MF and other MPNs, and its greatest benefits are related to improvement in spleen pain and discomfort, anemia and thrombocytopenia. However, in patients with MF it appears to be associated with increased mortality.

KW - Acute myeloid leukemia

KW - Myelofibrosis

KW - Myeloproliferative neoplasms

KW - Splenectomy

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84891360270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891360270&partnerID=8YFLogxK

U2 - 10.3109/10428194.2013.794269

DO - 10.3109/10428194.2013.794269

M3 - Article

C2 - 23573823

AN - SCOPUS:84891360270

VL - 55

SP - 121

EP - 127

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 1

ER -